Ⅰ、Ⅱ类整合子在变形菌属中的分布及耐药性研究

Study of the distribution and drug resistance of ClassⅠandⅡintegrons in Bacillus proteus

目的了解Ⅰ、Ⅱ类整合子在变形菌属中的分布及其耐药性,为临床合理选用抗菌药物提供参考依据。方法 125株变形菌属采用聚合酶链式反应扩增Ⅰ、Ⅱ类整合酶基因,微量稀释法测定细菌对抗菌药物的药敏率。结果 125株变形菌属中检出携带Ⅰ类整合子46株占38.60%,检出携带Ⅱ类整合子32株占25.60%,同时携带Ⅰ、Ⅱ类整合子17株,阳性率为13.60%;携带Ⅰ类或Ⅱ类整合子或同时两种整合子的菌株对阿米卡星、庆大霉素、妥布霉素、氨苄西林、环丙沙星、哌拉西林、头孢哌酮、头孢吡肟耐药率高于整合子阴性菌株,差异有统计学意义(P<0.05);携带有Ⅰ、Ⅱ类整合子的变形菌属对庆大霉素、环丙沙星、氨苄西林、哌拉西林、头孢哌酮的耐药率均>60.00%;125株变形菌属对哌拉西林/他唑巴坦、头孢西丁耐药率均<10.00%。结论临床分离的变形菌属中携带Ⅰ、Ⅱ类整合子的菌株比例较高,Ⅰ、Ⅱ类整合子与变形菌属的多药耐药具有相关性,临床上需合理应用抗菌药物,避免新耐药菌株的产生。

OBJECTIVE To investigate the distribution and drug resistance of Class Ⅰ and Ⅱ integrons in Bacillus proteus, and provide the basis for the rational clinical use of antimicrobial agents. METHODS Class Ⅰ and Class Ⅱ integrons from 125 B. proteus isolates were amplified by polymerase chain reaction. The drug sensitivity of the bacteria to 13 antimicrobial agents was detected by minimal inhibitory concentration. RESULTS Of the 125 strains, 36.80% strains harbored Class Ⅰ integron and 25.60% strains harbored Class Ⅱintegron. Only 13.60% strains harbored both Class Ⅰ and Class Ⅱ integrons. The drug resistance to amikacin, cidomycin, tenebrimycin, ampicil, ciprofloxacin, piperacillin, cefoperazone and cefepime of those strains harboring either one kind of integrons or harboring both kinds of integrons were significant higher than those of the strains without integrons, and the differences were significant （P〈0.05）. The drug resistance rates of the strains harboring ClassⅠ and Class Ⅱ integrons to cidomycin, ampicil, ciprofloxacin, piperaeillin, cefoperazone were all above 60.00%. The drug resistance rates of 125 strains of B. proteus to piperacillin/tazobactam and cefoxitin were all less than 10.00%. All strains were sensitive to imipenem. CONCLUSION The ratios of Class Ⅰ , Ⅱ integron are high in the clinically isolated B. proteus. Harboring ClassⅠ , Ⅱ integron is related to the muhi-drug resistance of B. proteus. Antimierobial agents should be rationally used in clinical treatment to avoid the generation of novel resistance genotypes.